Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating Biomarkers

Laura Housman's Biography



Laura Housman, Global Head, Pharmaceutical Business; Senior Vice President, Corporate Development, Molecular Health

Ms. Housman has nearly 25 years of US and European experience in healthcare delivery with particular emphasis on market access for oncology and diagnostics; early phase drug development marketing expertise, particularly in discovery, preclinical and first-in-human studies; and community leadership and support for women's health and development initiatives. She has extensive due diligence, transaction, investor and integration experience in large, small and start-up company settings and has successfully launched over 15 products and services across diagnostics, software and drug development, expanding market access and revenue opportunities globally. In addition to her professional work, Ms. Housman is on the faculty of the Tufts School of Medicine in Boston, MA. In addition, she is a member of the 3-person Board of Health serving Framingham, MA, a community of 70,000 residents in the Greater Boston area. Ms. Housman holds a Master of Business Administration with honors from Boston University Graduate School of Management; a Master of Public Health with specialization in Health Services from Boston University School of Public Health; and a Bachelor of Arts degree in Economics with a minor in Business Administration from Boston University College of Arts and Sciences.

Laura Housman Image

Exploring the Intersection of Precision Medicine and Population Health: Avoiding a Zero Sum Game

Tuesday, 22 March 2016 at 11:30

Add to Calendar ▼2016-03-22 11:30:002016-03-22 12:30:00Europe/LondonExploring the Intersection of Precision Medicine and Population Health: Avoiding a Zero Sum GameSELECTBIOenquiries@selectbiosciences.com

Precision/personalized medicine is clearly having its moment in the sun.  From publications to funding the emphasis on targeted therapies as well as gene-based testing and biomarker discoveries has been extensive and expanding. However, little has changed in the understanding of underlying disease- its etiology, prevention and management. Are there ways to harness the power and promise of precision medicine in support of population health goals?  Can “precision health management” become the next new thing?


Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonRNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating BiomarkersSELECTBIOenquiries@selectbiosciences.com